CRISPR Therapeutics Azioni (NASDAQ: CRSP)

CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Russia,Moscow,24.06.2021,Logo,Of,Financial,Investing,Fund,Ark,Invest

Equities

News

Markets

ETFs

ARKK

ARKW

ARKX

CRSP

KTOS

PACB

PLTR

SHOP

Movimenti sui fondi ETF della nota investitrice. Cessioni del titolo AI, acquisti mirati su chip ed e-commerce. Attività anche su biotech.

Cathie Wood vende Palantir prima degli utili e acquista questi 2 titoli

Long Ideas

Media

Trading Ideas

COST

DLTR

DXCM

Jim Cramer consiglia di acquistare Oneok, elogiando i risultati eccellenti e il potenziale di crescita della società.

Jim Cramer: questo titolo è un vero e proprio affare!

CRISPR Therapeutics AG

Press Releases

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Earnings

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

Health Care

General

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation

CRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025

Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth

Small Cap

Opinion

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

ADIA

CLDI

CTMX

FATE

IBRX

LCTX

MESO

VRTX

Abivax

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

BridgeBio Pharma

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Merus

Nuvalent

Vaxcyte

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

TG Therapeutics

Viking Therapeutics

HC Wainwright & Co.

Barclays

Chardan Capital

RBC Capital

B of A Securities

Comments

CRISPR Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO